Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes - PubMed (original) (raw)
. 1993 Aug 1;151(3):1235-44.
Affiliations
- PMID: 8393043
Anti-cytokine antibodies as carrier proteins. Prolongation of in vivo effects of exogenous cytokines by injection of cytokine-anti-cytokine antibody complexes
F D Finkelman et al. J Immunol. 1993.
Abstract
Anti-cytokine antibodies that block interactions between cytokines and cytokine receptors have been used to inhibit endogenous cytokine function. However, injection of mice with mixtures of IL-4 and either of two neutralizing anti-IL-4 mAb, at a cytokine/anti-cytokine mAb molar ratio of approximately 2:1, enhances and prolongs in vivo IL-4 activity, as measured by induction of increased spleen cell Ia expression. Although splenocyte Ia expression returns to baseline two days after mice are injected with free IL-4, soluble IL-4-anti-IL-4 mAb complexes still induce several-fold increases in Ia expression 3 days after injection. Complexes that contain as little as 400 ng of IL-4 have considerable in vivo stimulatory activity, and a maximal effect on splenocyte Ia expression is induced by injection of 2 micrograms of complexed IL-4. The stimulatory effect of IL-4-containing complexes on splenocyte Ia expression can be blocked by increasing the ratio of anti-IL-4 mAb to IL-4, by injection of anti-IL-4R mAb, and by in vivo aggregation of the complexes. Complexes of IL-4 with a non-neutralizing anti-IL-4 mAb do not have increased IL-4 agonist activity in vivo. These observations are most consistent with the possibility that neutralizing anti-IL-4 mAb act as carrier proteins that increase the in vivo half-life of IL-4 by preventing its excretion, and possibly, by preventing modification of its active site. The enhanced agonist effect of IL-4-anti-IL-4 mAb complexes is not unique; complexes of IL-3 with a neutralizing anti-IL-3 mAb have a greatly increased ability, compared with free IL-3, to stimulate mucosal mastocytosis, and complexes of IL-7 with a neutralizing anti-IL-7 mAb have a greatly increased ability, compared with free IL-7 or IL-7 complexed with a non-neutralizing anti-IL-7 mAb, to stimulate an increase in pre-B cell number. These observations suggest that complexes of cytokines and neutralizing anti-cytokine mAb may provide a generally useful way to increase the magnitude and duration of cytokine effects in vivo.
Similar articles
- Production of BSF-1 during an in vivo, T-dependent immune response.
Finkelman FD, Ohara J, Goroff DK, Smith J, Villacreses N, Mond JJ, Paul WE. Finkelman FD, et al. J Immunol. 1986 Nov 1;137(9):2878-85. J Immunol. 1986. PMID: 3489779 - Recombinant soluble murine IL-4 receptor can inhibit or enhance IgE responses in vivo.
Sato TA, Widmer MB, Finkelman FD, Madani H, Jacobs CA, Grabstein KH, Maliszewski CR. Sato TA, et al. J Immunol. 1993 Apr 1;150(7):2717-23. J Immunol. 1993. PMID: 8454851 - In vivo biological effects of recombinant soluble interleukin-4 receptor.
Maliszewski CR, Sato TA, Davison B, Jacobs CA, Finkelman FD, Fanslow WC. Maliszewski CR, et al. Proc Soc Exp Biol Med. 1994 Jul;206(3):233-7. doi: 10.3181/00379727-206-43750. Proc Soc Exp Biol Med. 1994. PMID: 8016157 Review. - Cytokine/Antibody complexes: an emerging class of immunostimulants.
Mostböck S. Mostböck S. Curr Pharm Des. 2009;15(7):809-25. doi: 10.2174/138161209787582174. Curr Pharm Des. 2009. PMID: 19275644 Review.
Cited by
- IL-7/anti-IL-7 mAb complexes augment cytokine potency in mice through association with IgG-Fc and by competition with IL-7R.
Martin CE, van Leeuwen EM, Im SJ, Roopenian DC, Sung YC, Surh CD. Martin CE, et al. Blood. 2013 May 30;121(22):4484-92. doi: 10.1182/blood-2012-08-449215. Epub 2013 Apr 22. Blood. 2013. PMID: 23610371 Free PMC article. - IL-2/anti-IL-2 mAb immunocomplexes: A renascence of IL-2 in cancer immunotherapy?
Tomala J, Kovar M. Tomala J, et al. Oncoimmunology. 2015 Nov 3;5(3):e1102829. doi: 10.1080/2162402X.2015.1102829. eCollection 2016 Mar. Oncoimmunology. 2015. PMID: 27141363 Free PMC article. Review. - The STAT5-GATA2 pathway is critical in basophil and mast cell differentiation and maintenance.
Li Y, Qi X, Liu B, Huang H. Li Y, et al. J Immunol. 2015 May 1;194(9):4328-38. doi: 10.4049/jimmunol.1500018. Epub 2015 Mar 23. J Immunol. 2015. PMID: 25801432 Free PMC article. - Naive CD8+ T cells differentiate into protective memory-like cells after IL-2 anti IL-2 complex treatment in vivo.
Kamimura D, Bevan MJ. Kamimura D, et al. J Exp Med. 2007 Aug 6;204(8):1803-12. doi: 10.1084/jem.20070543. Epub 2007 Jul 30. J Exp Med. 2007. PMID: 17664293 Free PMC article. - Effects of interleukin-4 deprivation and treatment on resistance to Trypanosoma cruzi.
Abrahamsohn IA, da Silva AP, Coffman RL. Abrahamsohn IA, et al. Infect Immun. 2000 Apr;68(4):1975-9. doi: 10.1128/IAI.68.4.1975-1979.2000. Infect Immun. 2000. PMID: 10722591 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous